Osteoporosis

Better cardiovascular health significantly reduced the risk for bone fractures related to osteoporosis, according to results from a cross-sectional study.

The FDA has approved two new biosimilars of denosumab to treat osteoporosis, increase bone mass, prevent skeletal-related events for people with multiple myeloma and other indications, Samsung Bioepis announced.

Topical formulation repairs skin thinning, fragility and bruising as a result of aging, according to a press release.

Early postmenopausal women who receive zoledronate every 5 years have a lower risk for morphometric vertebral fractures than those receiving placebo, according to trial findings published in The New England Journal of Medicine.

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according to a presentation at World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.

In a final recommendation statement, the U.S. Preventive Services Task Force said that all women aged 65 years and older should be screened for osteoporosis to prevent fractures.

Among adults with osteoporosis on dialysis, use of denosumab significantly lowered fracture risk compared with bisphosphonate use, but cardiovascular risk was increased, according to study data.

Osteoporosis prevalence is high for patients undergoing lung cancer screening, regardless of race, ethnicity and income, but CT with AI detects osteoporosis and body composition without additional testing or radiation, researchers reported.

Women with pregnancy and lactation-induced osteoporosis reported fewer disease-related fears or concerns after joining an online peer support group and sharing their health care experiences, researchers reported.

Having GERD, diabetes or osteoporosis in addition to COPD heightened the likelihood for exacerbations, ED visits and hospitalizations, according to results published in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation.